STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABCL
  4. [8-K] AbCellera Biologics Inc. Reports Material Event

AbCellera (Nasdaq: ABCL) Q2 loss widens as Jazz, Vertex deals add cash

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

AbCellera Biologics Inc. reported Q2 2026 financial and operational results. Total revenue was $4.1 million, compared with $17.1 million in Q2 2025, and the company posted a net loss of $55.4 million, or $(0.18) per share, versus a net loss of $34.7 million, or $(0.12) per share, a year earlier.

The company highlighted pipeline progress, including completed enrollment in the Phase 2 trial of ABCL635 with top-line data expected in August 2026, and completed dosing in the Phase 1 study of ABCL575 with data expected in Q4 2026. ABCL386 and ABCL688 are in IND-enabling activities, and partners led 35 programs with downstream participation, including 12 molecules in the clinic as of June 30, 2026.

AbCellera expanded its T-cell engager collaborations, signing a Jazz Pharmaceuticals agreement with $84 million in total upfront payments and eligibility for up to $792 million per program in option and milestone payments plus tiered royalties, and a Vertex collaboration providing $28 million in upfront payments with further milestone and royalty potential. The company emphasized a strong liquidity position with over $565 million in cash balances and marketable securities and more than $675 million in total available liquidity, including $110 million in available non-dilutive government funding.

Positive

  • $84 million in total upfront payments from a new Jazz Pharmaceuticals T-cell engager collaboration, with up to $792 million per program in potential option and milestone payments plus tiered royalties on net sales.
  • New Vertex Pharmaceuticals collaboration adds $28 million in total upfront payments and potential preclinical, development, regulatory, and commercial milestones along with tiered royalties on net sales.
  • Robust liquidity, with over $565 million in cash balances and marketable securities and more than $675 million in total available liquidity supported by about $110 million in available non-dilutive government funding.

Negative

  • Quarterly revenue declined to $4.1 million in Q2 2026 from $17.1 million in Q2 2025, reflecting a substantial year-over-year drop in topline.
  • Net loss widened to $55.4 million, or $(0.18) per share, compared with a net loss of $34.7 million, or $(0.12) per share, in Q2 2025.
  • Research and development spending increased to $46.0 million in Q2 2026 while total operating expenses remained high at about $66.8 million.

Filing Explained

At June 30, 2026, AbCellera reported 306,469,632 common shares outstanding, up from 300,600,710 at December 31, 2025.

Form 8-K reports specified material events, and this filing furnishes AbCellera’s second-quarter results and presentation; the supplied materials are not treated as filed for Section 18 liability purposes.

At June 30, 2026, common shares issued and outstanding totaled 306,469,632, compared with 300,600,710 at December 31, 2025. This establishes a higher reported share count for existing holders to assess, but the filing does not identify the change as a financing or state proceeds or dilution.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 Revenue $4.1 million Total revenue for the quarter ended June 30, 2026
Q2 2025 Revenue $17.1 million Total revenue for the quarter ended June 30, 2025
Q2 2026 Net Loss $55.4 million Net loss for the quarter ended June 30, 2026
Q2 2025 Net Loss $34.7 million Net loss for the quarter ended June 30, 2025
Cash and Marketable Securities over $565 million Total cash balances and marketable securities at June 30, 2026
Total Available Liquidity over $675 million Cash, marketable securities, and available non-dilutive government funding
Jazz Upfront Payments $84 million Total upfront payments from Jazz Pharmaceuticals T-cell engager collaboration
Vertex Upfront Payments $28 million Total upfront payments from Vertex Pharmaceuticals collaboration
T-cell engagers (TCEs) medical
"next-generation T-cell engagers (TCEs) for multiple gastrointestinal cancers"
IND-enabling activities regulatory
"ABCL386 and ABCL688 are progressing through IND-enabling activities."
IND-enabling activities are the lab tests, animal studies and manufacturing checks a company performs to demonstrate a new drug is reasonably safe and can be produced reliably before filing an Investigational New Drug (IND) application to begin human trials. For investors these steps are a key milestone because completing them reduces safety and regulatory risk, requires substantial time and funding, and signals that a program is ready to move from early development into clinical testing—like building a foundation before constructing a house.
deferred revenue financial
"Deferred revenue | 13,526 | | | 20,705"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
non-dilutive government funding financial
"available non-dilutive government funding, bringing total available liquidity"
Non-dilutive government funding is money a company receives from a government—such as grants, contracts, tax credits, or low-interest loans—that does not require issuing new shares or giving up ownership. For investors, it matters because it funds growth or R&D without shrinking existing shareholders’ stake, extending a company’s cash runway and reducing the need to sell equity; think of it as a subsidy or loan that preserves ownership while de-risking projects.
tiered royalties financial
"tiered royalties on net sales ranging from mid-single digits to low double digits"
Tiered royalties are a payment structure where the percentage of earnings paid as royalties changes based on different levels of sales or production. For example, a company might pay a smaller percentage on initial sales and a higher percentage as sales increase beyond certain points. This system encourages higher sales by adjusting payments, making it important for investors to understand how revenue sharing may vary as a product or project grows.
Q2 2026 revenue $4.1 million decreased from $17.1 million in Q2 2025
Q2 2026 net loss $55.4 million widened from $34.7 million in Q2 2025
Q2 2026 R&D expenses $46.0 million increased from $39.2 million in Q2 2025
Q2 2026 SG&A expenses $13.9 million decreased from $22.0 million in Q2 2025

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were AbCellera (ABCL) Q2 2026 revenue and net loss?
AbCellera reported Q2 2026 revenue of $4.1 million and a net loss of $55.4 million. In Q2 2025, revenue was $17.1 million and net loss was $34.7 million, showing lower revenue and a larger loss versus the prior year.

How strong is AbCellera (ABCL) liquidity after Q2 2026?
AbCellera ended Q2 2026 with over $565 million in cash balances and marketable securities and more than $675 million in total available liquidity. This includes about $110 million in available non-dilutive government funding to support its strategy and R&D programs.

What is the Jazz Pharmaceuticals collaboration AbCellera (ABCL) announced?
AbCellera announced a multi-program T-cell engager collaboration with Jazz Pharmaceuticals, with $84 million in total upfront payments. The company is eligible for up to $792 million per program in option, development, regulatory, and commercial milestones, plus tiered royalties on net sales.

What are the key details of AbCellera (ABCL) collaboration with Vertex?
AbCellera entered a collaboration with Vertex Pharmaceuticals focused on multispecific T-cell engagers for autoimmune diseases and other conditions. AbCellera receives $28 million in total upfront payments and may earn preclinical, development, regulatory, and commercial milestones, plus tiered royalties on net sales.

What is the clinical status of AbCellera (ABCL) programs ABCL635 and ABCL575?
Enrollment is complete for the Phase 2 trial of ABCL635, with top-line data expected in August 2026. Dosing is complete in the Phase 1 study of ABCL575, with top-line data readout expected in Q4 2026, supporting AbCellera’s move into later-stage clinical development.

How many partnered programs and clinical molecules does AbCellera (ABCL) have?
At the end of Q2 2026, partners led 35 programs in which AbCellera holds a downstream stake. In total, AbCellera had downstream interests in 12 molecules understood to be progressing in clinical trials as of June 30, 2026.
0001703057falseVancouverBC00017030572026-08-052026-08-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 5, 2026
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
British Columbia001-39781Not Applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue
Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 2.02    Results of Operations and Financial Condition
On August 5, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01    Regulation FD
In connection with its earnings call on August 5, 2026, to discuss its results for the quarter ended June 30, 2026, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.
The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01    Financial Statements and Exhibits
(d)Exhibits
Exhibit
No.		Description
99.1
Press Release issued by AbCellera Biologics Inc. on August 5, 2026.
99.2
Corporate Presentation.
104Cover Page Interactive Data File (embedded as Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 5, 2026ABCELLERA BIOLOGICS INC.
By:/s/ Carl L. G. Hansen
Carl L. G. Hansen, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)


NEWS RELEASE


AbCellera Reports Q2 2026 Business Results

8/5/2026


VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Since our last business update we signed two new collaborations, one with Jazz and one with Vertex, that leverage our T-cell engager platform to advance programs into the clinic and are adding over $100 million in upfront cash to our balance sheet.”

Q2 2026 Business Summary and Program Updates
●ABCL635 top-line data readout from the Phase 2 trial expected in August 2026.
●ABCL386 and ABCL688 are progressing through IND-enabling activities.
●Announced collaboration with Jazz Pharmaceuticals plc to discover and develop next-generation T-cell engagers (TCEs) for multiple gastrointestinal cancers and other solid tumors. AbCellera is receiving $84 million in total upfront payments, with $56 million for the first two research programs and $28 million for a third program, which will initiate within 12 months. AbCellera is eligible to receive up to $792 million per program in option fees and development, regulatory, and commercial sales milestone payments along with tiered royalties on net sales ranging from mid-single digits to low double digits.
●Completed dosing for the Phase 1 study of ABCL575, with top-line data readout expected in Q4 2026.
●Announced the appointments of Dr. Victor Sandor and Dr. Lynn Seely as independent directors to AbCellera’s board of directors.
●Generated a net loss of $55.4 million, compared to a net loss of $34.7 million in Q2 2025.
●Ended the quarter with over $565 million in total cash balances and marketable securities, providing over $675 million in total available liquidity to execute on AbCellera’s strategy.

Subsequent Event
●On July 29, 2026 announced a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific TCEs for autoimmune diseases and other conditions. AbCellera will receive $28 million in total
1

upfront payments and is eligible to receive preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales.

Discussion of Q2 2026 Financial Results
●Revenue – Total revenue was $4.1 million, compared to $17.1 million in Q2 2025.
●Research & Development (R&D) Expenses – R&D expenses were $46.0 million, compared to $39.2 million in Q2 2025.
●Sales, General, & Administrative (SG&A) Expenses – SG&A expenses were $13.9 million, compared to $22.0 million in Q2 2025.
●Net Loss – Net loss of $55.4 million, or $(0.18) per share on a basic and diluted basis, compared to net loss of $34.7 million, or $(0.12) per share on a basic and diluted basis, in Q2 2025.
●Available Liquidity – over $565 million in total cash balances and marketable securities, and $110 million in available non-dilutive government funding, bringing total available liquidity to over $675 million to execute on AbCellera's strategy.

Business Metrics
At the end of Q2 2026, partners led 35 programs that AbCellera believes to be progressing and where AbCellera holds a downstream stake (down from 44 on December 31, 2025). In total, AbCellera held downstream stakes in 12 molecules in the clinic understood to be progressing on June 30, 2026.

Conference Call and Webcast
AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com.

AbCellera Forward-Looking Statements
This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives
2

for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
3

AbCellera Biologics Inc.
Condensed Consolidated Statements of Loss and Comprehensive Loss
(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)
(Unaudited)

Three months ended June 30,Six months ended June 30,
2025202620252026
Revenue:
Research fees$6,639 $3,901 $10,707 $12,021 
Licensing and royalty revenue10,445 149 10,613 341 
Total revenue17,084 4,050 21,320 12,362 
Operating expenses:
Research and development(1)
39,213 45,987 81,711 92,649 
Sales, general, and administrative(1)
21,986 13,850 41,054 26,185 
Depreciation and amortization5,470 6,990 10,801 13,828 
Total operating expenses66,669 66,827 133,566 132,662 
Loss from operations(49,585)(62,777)(112,246)(120,300)
Other (income) expense:
Interest and other(9,549)42 (15,073)(3,606)
Grants and incentives(3,692)(3,854)(7,845)(8,193)
Total other income(13,241)(3,812)(22,918)(11,799)
Loss before income tax(36,344)(58,965)(89,328)(108,501)
Income tax recovery(1,617)(3,538)(8,980)(9,909)
Net loss$(34,727)$(55,427)$(80,348)$(98,592)
Foreign currency translation adjustment4,341 (733)1,721 1,082 
Comprehensive loss$(30,386)$(56,160)$(78,627)$(97,510)
Net loss per share
Basic$(0.12)$(0.18)$(0.27)$(0.32)
Diluted$(0.12)$(0.18)$(0.27)$(0.32)
Weighted-average common shares outstanding
Basic298,508,601305,557,294298,105,760304,329,623
Diluted298,508,601305,557,294298,105,760304,329,623

(1) Exclusive of depreciation and amortization
4

AbCellera Biologics Inc.
Condensed Consolidated Balance Sheets
(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)
(Unaudited)
December 31, 2025June 30, 2026
Assets
Current assets:
Cash and cash equivalents$128,513 $120,065 
Marketable securities405,313 420,039 
Total cash, cash equivalents, and marketable securities533,826 540,104 
Accounts and accrued receivable58,293 18,597 
Restricted cash25,000 25,000 
Other current assets111,113 95,529 
Total current assets728,232 679,230 
Long-term assets:
Property and equipment, net428,003 416,677 
Intangible assets, net38,381 36,530 
Goodwill47,806 47,806 
Investments in equity accounted investees62,580 65,229 
Other long-term assets51,948 62,103 
Total long-term assets628,718 628,345 
Total assets$1,356,950 $1,307,575 
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other current liabilities$50,781 $32,484 
Deferred revenue13,526 20,705 
Total current liabilities64,307 53,189 
Long-term liabilities:
Operating lease liability137,403 129,948 
Deferred revenue3,500 40,450 
Deferred government contributions174,453 178,254 
Other long-term liabilities10,383 9,714 
Total long-term liabilities325,739 358,366 
Total liabilities390,046 411,555 
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2025 and June 30, 2026: 300,600,710 and 306,469,632 shares issued and outstanding at December 31, 2025 and June 30, 2026, respectively
802,341 821,242 
Additional paid-in capital198,279 206,004 
Accumulated other comprehensive loss(4,234)(3,152)
Accumulated deficit(29,482)(128,074)
Total shareholders' equity966,904 896,020 
Total liabilities and shareholders' equity$1,356,950 $1,307,575 
5

AbCellera Biologics Inc.
Condensed Consolidated Statement of Cash Flows
(Expressed in thousands of U.S. dollars.)
(Unaudited)

Six months ended June 30,
20252026
Cash flows from operating activities:
Net loss$(80,348)$(98,592)
Cash flows from operating activities:
Depreciation of property and equipment8,951 11,977 
Amortization of intangible assets1,851 1,851 
Amortization of operating lease right-of-use assets2,863 3,610 
Stock-based compensation28,993 24,299 
Other70 7,019 
Changes in operating assets and liabilities:
Research fees and grants receivable(12,524)25,367 
Income taxes receivable(7,588)(8,024)
Accounts payable and accrued liabilities(7,356)(16,621)
Deferred revenue9,361 44,129 
Deferred grant income(1,681)(4,453)
Other assets13,450 1,838 
Net cash used in operating activities(43,958)(7,600)
Cash flows from investing activities:
Purchases of property and equipment(24,001)(5,963)
Purchase of marketable securities(291,542)(308,184)
Proceeds from marketable securities303,437 293,557 
Receipt of grant funding6,448 6,955 
Long-term investments and other assets(18,218)(105)
Net cash used in investing activities(23,876)(13,740)
Cash flows from financing activities:
Proceeds from deferred government contributions and other2,595 13,585 
Net cash provided by financing activities2,595 13,585 
Effect of exchange rate changes on cash and cash equivalents1,351 (468)
Decrease in cash and cash equivalents(63,888)(8,223)
Cash and cash equivalents and restricted cash, beginning of period183,615 155,249 
Cash and cash equivalents and restricted cash, end of period$119,727 $147,026 
Restricted cash included in other assets2,290 1,961 
Total cash, cash equivalents, and restricted cash shown on the balance sheet$117,437 $145,065 
Supplemental disclosure of non-cash investing and financing activities
Property and equipment in accounts payable12,733 979 
Right-of-use assets obtained in exchange for operating lease obligation69,787 – 






6

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.
7
CO PY RI GH T © A BC EL LE RA AUGUST 5, 2026 Q2 2026 BUSINESS UPDATE

 

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. DISCLAIMER This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. 2 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 B us in es s U pd at e

 

3 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e ABCL635 patient enrollment closed, Phase 2 readout in Q3, and all programs in the pipeline progressing 2026 PRIORITIES UPDATE Nominate at least 1 additional development candidate for IND-enabling activities ABCL635 Phase 2 clinical trial top-line readout in Q3 2026 ABCL575 Phase 1 clinical trial top-line readout in Q4 2026 ABCL688 progressing through IND-enabling activities ABCL386 progressing through IND-enabling activities Enrollment complete Dosing complete

 

4 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e We are using our TCE platform to advance programs into the clinical both internally and through strategic collaborations Novel TCE building blocks Proprietary panels of CD3-binding antibodies and costimulatory antibodies to fine- tune TCE function. A scalable process to assess TCE function Established tools, workflows, and high- throughput in vitro assays to systematically test hundreds of diverse molecules and multiple modalities. Experience across diverse targets Applying expertise and a deep understanding of TCE biology drawn from internal and partner- initiated bispecific programs on diverse targets and modalities. 2x1 T-CELL ENGAGER PLATFORM Our TCE platform is fully integrated with end-to-end capabilities, from discovery to manufacturing: Recent TCE deals are adding $112M in upfront cash to our balance sheet

 

5 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Collaboration with Vertex to advance programs in autoimmunity PARTNERING: TCE COLLABORATIONS Multi-target collaboration in autoimmune disease and other conditions $28M Eligible for potential downstream payments and tiered royalties on net sales. total upfront payments OPTIONAL: SCOPE EXPANSION If mutually agreed, AbCellera could perform cell line development, process development, and clinical manufacturing through Phase 1.

 

6 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Collaboration with Jazz to advance programs in oncology PARTNERING: TCE COLLABORATIONS 3 Discovery Programs OPTIONAL: PROGRAM EXPANSION 2 Additional Discovery Programs $2.5B ● $84M in total upfront payments ($56M of which received in Q2) Mid-single digit to low double digit tiered royalties on net sales. total potential payments $1.6B ● $56M in total potential upfront payments Mid-single digit to low double digit tiered royalties on net sales. total potential payments AbCellera could undertake certain IND-enabling activities and clinical manufacturing. OPTIONAL: SCOPE EXPANSION

 

7 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e We welcome Dr. Victor Sandor and Dr. Lynn Seely as independent directors to AbCellera’s board of directors Dr. Victor Sandor Dr. Lynn Seely

 

8 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Q2 2026 FINANCIALS UPDATE

 

9 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e We continue to maintain a strong liquidity position to execute on our strategy * As of June 30, 2026 in total available government funding*~$110M in total cash balances & marketable securities*>$565M in available liquidity to execute on our strategy*>$675M

 

10 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e RESEARCH & DEVELOPMENT SALES, GENERAL & ADMIN Operating expenses reflect R&D investments Operating Expenses USDRevenue USD MILESTONES RESEARCH FEES LICENSING AND ROYALTY Q2 2025 Q2 2026 $17.1M $4.1M Q2 2025 Q2 2026 $39.2M $46.0M +$6.8M Q2 2025 Q2 2026 $22.0M $13.9M -$8.1M

 

11 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Net loss of $55M; equivalent to ($0.18) per share (basic & diluted) Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED Q2 2025 Q2 2026 ($34.7M) ($55.4M) Q2 2025 Q2 2026 ($0.12) ($0.18)

 

12 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Over $565M in total cash balances and marketable securities Cash Flows USD * Restricted cash (including restricted cash in other assets)

 

13 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e THANK YOU

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents